Analisis Efektivitas Pengikat Fosfat Tablet Kalsium Karbonat yang Dikunyah Dibandingkan yang Ditelan Utuh pada Pasien Penyakit Ginjal Kronis Dengan atau Tanpa Gangguan Saluran Cerna

Galuh Nawang Prawesti, R. Moh. Yogiantoro, Gunawan Widodo, Anita Purnamayanti


Chronic Kidney Disease (CKD) patient with Mineral and Bone Disorder complication have to chew calcium carbonate tablet as a phosphate binder, but infact, patient swallow it in a whole. Gastrointestinal (GI) disorders can affect the efficacy of medicine. This study aims to analyze the effectiveness comparation of chewed and whole swallowed calcium carbonate tablet in CKD patients with or without gastrointestinal disorders. This prospective quasi experimental study with non-inferiority design was conducted on May 28th to August 22nd 2012, with 22 sample (stage 3-5 CKD), 14 men, 8 women, divided into 4 groups (1st: patients with GI disorder and whole swallowed calcium carbonate, 2nd: with GI disorders and chewed tablet, 3rd: without GI disorders and whole swallowed tablet, 4th group: without GI disorders and chewed tablet, all tablet are used with meal). Before and after the 6th week research period, calcium and phosphate blood levels measurements had been taken, adherence had been measured every two weeks using the Morisky questionnaire and pill count. The results showed that there was no significant difference in the increased of calcium levels, except for group 1 compared to group 3 (p = 0.027), the decreased phosphate levels (p = 0.724; 0.089; 0.089; 0.414; 0.569; 1.000) and the value of the product calcium-phosphate (p = 1.000; 0.308; 0.186; 0.414; 0.425; 0.728). The conclusion is that the way to use the medicine and the states of gastrointestinal disorders did not significantly influence the effectiveness of calcium carbonate tablet.

Save to Mendeley

Full Text:



Arenas MD, Malek T, Álvarez-Ude F, Gil1 MT, Moledous A, Reig-Ferrer A, 2010, Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control, Nefrologia, 30(5), 522-30.

Ashley C, Morlidge C, 2008, Introduction to renal therapeutics, Cambridge University Press, London, 38-41.

ASKES, 2010, cited 5 Desember 2011, available from:

Coladonato JA, 2005, Control of hyperphosphatemia among patients with ESRD. Journal of the American Society of Nephrology, 16, S107–S114.

Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, 2008, Pharmacotherapy : a pathophysiologic approach, 7th ed, McGraw-Hill, New York.

Ekman M, Reizenstein P, Teigen SW, Ronneberg R, 1991, Comparative absorption of calcium from carbonate tablets, lactogluconate/carbonate effervescent tablet, and chloride solution. Bone, 12(2), 93-7.

Hutchison AJ, 2009, Oral phosphate binders, International Society of Nephrology.

Indian Health Service National Pharmacy and Therapeutics Committee, 2010, Phosphate binders used in chronic kidney disease

Karamanidou C, Clatworthy J, Weinman J, Horne R, 2008, A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease, BioMed Central Nephrol, 9(2), 1-10.

Medscape Pharmacist education, 2010, cited 2011 November 23th, available from

National Institute of Diabetes and Digestive and Kidney Diseases, 2005, Renal Osteodystrophy, NIH Publication, 05–4630.

O’Callaghan CA, 2000, The renal system at a glance, 2nd ed., Blackwell, Oxford, 94-95.

PERNEFRI, 2009, Konsensus gangguan mineral dan tulang pada penyakit ginjal kronik (GMT-PGK), edisi 1.

Qunibi W, Winkelmayer WC, Solomon R, Moustafa M, Kessler P, Ho CH, et al., 2011, A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced nondialysis-dependent chronic kidney disease, BioMed Central Nephrology, 12:9.

Sweetman SC, Blake PS, McGlashan JM, Neathercoat GC, Parsons AV, Brayfield A, 2007, Martindale: The Complete Drug Reference, 35th Ed, The Pharmaceutical Press, London.

Thomas SA, 2000, How to write health sciences papers, dissertation and theses, Churchill livingstone, New York.

U.S. Departement of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2000, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally

Administered Drug Products-General Considerations, Center for Drug Evaluation and Research (CDER).

Williams III RO, Taft DR, McConville JT, 2008, Advanced Drug Formulation Design to Optimize Therapeutic Outcomes, Informa Healthcare USA, New York, 227.